Cananga latifolia

Cananga latifolia roots contain juvenile hormone III analogues (canangalias C–H) and structurally related terpenoids that modulate insect developmental pathways, while the closely related species Cananga odorata contributes oxoaporphine alkaloids such as liriodenine that inhibit topoisomerase II in cancer cell models. Preclinical evidence from C. odorata—the most pharmacologically studied congener—demonstrates that ethyl acetate fractions reduced glucose levels in diabetic Drosophila more effectively than metformin at 200 mg per 10 g of diet, and leaf volatile oils inhibited nitric oxide production with an IC50 of 37.61 µg/mL in LPS-stimulated macrophages, though no human clinical data exist for either species.

Origin & History

Cananga latifolia (Graham) King is a tropical tree native to Southeast Asia, distributed across the Malay Peninsula, Indonesia, and neighboring island regions, where it grows in lowland tropical forests and secondary vegetation at low to moderate elevations. It belongs to the Annonaceae family, closely related to Cananga odorata (ylang-ylang), and thrives in humid, warm climates with well-drained soils typical of equatorial rainforest zones. The species has been utilized in traditional Indonesian medicine, particularly in Javanese and Sumatran ethnobotanical traditions, though formal cultivation for medicinal or commercial purposes remains undocumented.

Historical & Cultural Context

Cananga latifolia occupies a modest but recognized place in Indonesian traditional medicine, where it has been used by indigenous communities—particularly in Sumatra and Java—as a remedy for rheumatism and wound treatment, applications consistent with the anti-inflammatory and antimicrobial properties later identified in vitro for related Annonaceae species. The Cananga genus as a whole holds cultural significance across Southeast Asia; its more celebrated relative, Cananga odorata, has been central to Javanese, Malay, and Filipino ceremonial and cosmetic traditions for centuries, suggesting that C. latifolia shared some of this ethnobotanical heritage in overlapping geographic ranges. Traditional preparation methods for C. latifolia have not been formally documented in peer-reviewed ethnobotanical surveys, though regional healers are understood to use root-based preparations, likely as poultices or decoctions, mirroring broader Annonaceae herbal traditions in the region. The species was first described botanically by Robert Graham and subsequently reclassified by King, and it remains understudied relative to its aromatic congener, with its medicinal applications largely preserved in oral tradition rather than written pharmacopeial records.

Health Benefits

- **Anti-inflammatory Activity**: Volatile oils from the related Cananga odorata suppress nitric oxide production in LPS-induced RAW264.7 macrophage cells with an IC50 of 37.61 µg/mL, suggesting modulation of inflammatory signaling pathways relevant to rheumatic conditions for which C. latifolia is traditionally used.
- **Antioxidant Properties**: Leaf volatile oils of C. odorata scavenge DPPH free radicals with an IC50 of 3.84 mg/mL, while ethyl acetate fractions reduce glutathione-S-transferase activity, thiol levels, nitric oxide, and hydrogen peroxide in oxidative stress bioassays, indicating broad radical-quenching capacity.
- **Antidiabetic Potential**: Ethyl acetate fractions of C. odorata administered at 200 mg per 10 g of diet outperformed metformin in reducing blood glucose in a Drosophila melanogaster hyperglycemia model, mediated at least partly through alpha-amylase inhibition with cananodine showing a docking binding energy of -41.63 kcal/mol.
- **Cytotoxic and Anticancer Activity**: Sesquiterpene alcohols cryptomeridiol 11-α-L-rhamnoside and γ-eudesmol isolated from C. odorata demonstrated potent cytotoxicity against Hep G2 and Hep 2,2,15 hepatocellular carcinoma cell lines in vitro, implicating terpenoid scaffolds conserved across the Cananga genus.
- **Topoisomerase II Inhibition**: Liriodenine, an oxoaporphine alkaloid identified in C. odorata and structurally consistent with Annonaceae alkaloid chemistry, inhibits DNA topoisomerase II both in vitro and in vivo, a mechanism exploited in several established anticancer drug classes.
- **Juvenile Hormone Modulation**: Six novel juvenile hormone III analogues (canangalias C–H) isolated from C. latifolia roots represent a unique class of bioactive terpenoids with potential insect endocrine-disrupting activity, relevant to biopesticide applications and indirectly informing understanding of terpenoid bioactivity in the genus.
- **Wound-Healing Ethnopharmacological Basis**: Traditional Indonesian use of C. latifolia for wound treatment aligns with the anti-inflammatory and antioxidant properties identified in congener species, suggesting a plausible ethnopharmacological rationale, though no mechanistic wound-healing studies have been conducted on C. latifolia specifically.

How It Works

In the closely related Cananga odorata, the oxoaporphine alkaloid liriodenine intercalates into DNA and inhibits topoisomerase II, an enzyme essential for DNA replication and transcription, thereby inducing apoptosis in rapidly dividing cancer cells both in vitro and in experimental in vivo models. Ethyl acetate fractions containing the alkaloid cananodine competitively inhibit Drosophila α-amylase (molecular docking binding energy: -41.63 kcal/mol), reducing carbohydrate hydrolysis and postprandial glucose availability, while simultaneously reducing oxidative stress biomarkers including glutathione-S-transferase activity, free thiols, nitric oxide, and hydrogen peroxide. Sesquiterpene-dominated volatile oils—particularly germacrene D, β-caryophyllene, spathulenol, and humulene epoxide-II—suppress LPS-stimulated inducible nitric oxide synthase (iNOS) activity in RAW264.7 macrophages (IC50 37.61 µg/mL), curtailing downstream neuroinflammatory and vascular inflammatory cascades. For C. latifolia specifically, the identified juvenile hormone III analogues (canangalias C–H) are structurally homologous to sesquiterpenoid signaling molecules that bind juvenile hormone receptors (methoprene-tolerant/Methoprene-tolerant, Met) in insects, though mammalian receptor targets and molecular pathways for these compounds remain entirely uninvestigated.

Scientific Research

The evidence base for Cananga latifolia as a medicinal ingredient is extremely limited, comprising a single phytochemical isolation study documenting thirteen juvenile hormone III analogues from roots with no biological activity data reported for the compounds in mammalian or clinical contexts. Research on the closely related Cananga odorata—from which mechanistic and efficacy inferences are cautiously extrapolated—consists entirely of in vitro cell assays (RAW264.7 macrophages, hepatocellular carcinoma lines) and in vivo Drosophila melanogaster experiments, none of which constitute adequate translational evidence for human clinical application. No randomized controlled trials, observational cohort studies, or human pharmacokinetic studies have been published for either C. latifolia or C. odorata, and sample sizes are unreported in the available animal and cell studies, precluding statistical evaluation of effect sizes. The overall body of evidence is preclinical, sparse, and largely restricted to isolated compound characterization and single-model bioactivity screens, placing this ingredient firmly in the exploratory research category.

Clinical Summary

No clinical trials in human participants have been conducted for Cananga latifolia or its botanical congener Cananga odorata as of the available literature. The most robust experimental data come from a Drosophila melanogaster model of hyperglycemia in which C. odorata ethyl acetate fractions at 200 mg per 10 g diet reduced blood glucose more than metformin, and from LPS-stimulated RAW264.7 macrophage assays where leaf volatile oils inhibited nitric oxide with an IC50 of 37.61 µg/mL—both representing early-stage, non-human evidence with no reported sample sizes or confidence intervals. Cytotoxicity against Hep G2 and Hep 2,2,15 hepatocellular carcinoma cell lines was noted for isolated sesquiterpene glycosides, but quantitative IC50 values and comparative benchmarks were not published in the accessible data. Confidence in any clinical application of C. latifolia is negligible given the complete absence of human pharmacological, pharmacokinetic, or safety data, and all purported benefits remain speculative pending properly designed translational studies.

Nutritional Profile

Cananga latifolia has not been characterized for macronutrient, micronutrient, or dietary nutritional content, and no proximate composition analyses have been published. Phytochemically, roots are confirmed to contain thirteen juvenile hormone III analogues including six novel canangalias (C–H) and the new natural product (2E,6E,10R)-10-acetoxy-11-hydroxy-3,7,11-trimethyldodeca-2,6-dienoic acid methyl ester, all belonging to the sesquiterpenoid and diterpenoid structural classes, though no quantitative concentrations (mg/g dry weight) were reported. By analogy with the closely related Cananga odorata, leaf and flower tissues of Cananga species contain sesquiterpenes (germacrene D, β-caryophyllene, spathulenol comprising up to 31.6% of leaf volatile oil), oxoaporphine alkaloids (liriodenine), and phenolic compounds, with volatile oil accounting for approximately 91.9% of identified leaf extract components across 63 individual compounds. Bioavailability data—including oral absorption, first-pass metabolism, protein binding, or tissue distribution—are entirely absent for C. latifolia compounds and have not been established for the analogous C. odorata phytochemicals in mammalian systems.

Preparation & Dosage

- **Root Extract (Ethanol/Unspecified Solvent)**: Used in the sole phytochemical isolation study of C. latifolia; no standardized dose, extract ratio, or preparation protocol has been established for human use.
- **Ethyl Acetate Fraction (C. odorata, Experimental)**: Applied at 200 mg per 10 g diet in Drosophila antidiabetic experiments; direct extrapolation to human dosing is not valid and no human equivalent dose has been calculated.
- **Essential Oil via Steam Distillation (C. odorata Leaves)**: Leaf volatile oil tested at 37.61 µg/mL (IC50) for nitric oxide inhibition in cell assays; no topical or inhalation dose for human application has been established.
- **Traditional Preparation (Indonesian Ethnomedicine)**: Roots and plant parts reportedly prepared as decoctions or topical poultices for rheumatism and wound care; specific water-to-plant ratios, preparation times, and applied quantities are undocumented in the scientific literature.
- **Standardization**: No standardized extract, certificate of analysis benchmarks, or active marker compound thresholds (e.g., canangalia or liriodenine percentage) have been established for any commercial or research-grade preparation of C. latifolia.

Synergy & Pairings

No formal synergy studies have been conducted for Cananga latifolia with any co-ingredient, and no evidence-based combination protocols have been published. By structural and pharmacological analogy with Cananga odorata, the sesquiterpene-rich volatile fraction (β-caryophyllene, germacrene D) may exhibit additive anti-inflammatory effects when combined with other CB2 receptor-active compounds such as copaiba resin or black pepper extract, given β-caryophyllene's established CB2 agonist activity in other botanical contexts, though this specific combination has not been tested for C. latifolia. The alpha-amylase inhibitory activity demonstrated for C. odorata alkaloids in Drosophila models could theoretically complement other carbohydrate-metabolizing enzyme inhibitors such as berberine or white mulberry leaf extract (1-deoxynojirimycin) in antidiabetic stacks, but no co-administration data exist to support or refute this hypothesis.

Safety & Interactions

No formal safety assessment, toxicology study, or adverse event documentation exists for Cananga latifolia in human populations or in mammalian animal models, making it impossible to define safe dose ranges, no-observed-adverse-effect levels (NOAELs), or risk thresholds for any route of administration. The closely related Cananga odorata demonstrates low acute cytotoxicity in cancer cell bioassays and shows anti-inflammatory effects in cell models at concentrations of 37.61 µg/mL, but this in vitro low-toxicity profile cannot be extrapolated to establish human safety without appropriate pharmacokinetic and toxicological studies. No drug interaction data are available; however, given that liriodenine (identified in C. odorata) inhibits topoisomerase II—a mechanism shared with chemotherapeutic agents such as doxorubicin and etoposide—theoretical pharmacodynamic interactions with cytotoxic drugs cannot be excluded if similar alkaloids are present in C. latifolia. Use during pregnancy and lactation, in pediatric populations, or in individuals with hepatic or renal impairment cannot be assessed and should be avoided until evidence-based safety data are generated; the ingredient should be regarded as experimental and not recommended for self-supplementation.